Cibus, Inc. (CBUS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 4 Margin 2 Expansion 5 Platform 4 Financial 3

latest quarter score

Earnings Reports

18
Cibus (CBUS) Q2 2026: Platform Scalability Drives 35% Revenue Growth Amid Regulatory Tailwinds
August 18, 2026
14
CBIS (CBUS) Q1 2026: $8M Expense Cut Accelerates Commercialization Path in Rice and Biofragrances
May 15, 2026
11
CBUS Q4 2025: $10M Cost Cuts Extend Runway as Regulatory Tailwinds Unlock $200M Rice Royalties
March 18, 2026
11
CBUS (CBUS) Q3 2025: Rice Trait Agreements Expand to 7 Million Acres, Unlocking $200M Royalty Path
November 14, 2025
10
CBUS (CBUS) Q2 2025: $200M Rice Royalty Path Drives Operational Refocus and Cash Discipline
August 14, 2025
15
Cibus (CBUS) Q1 2025: $21M Goodwill Impairment Overshadows Progress Amid Regulatory and Commercial Milestones
May 08, 2025
11
Cibus (CBUS) Q4 2024: Regulatory Advances and Trait Development Propel Commercialization Momentum
March 20, 2025

Browse all companies